Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2006 04:42 ET | Source: Jerini AG

Jerini AG Completes Randomization of Last Patient in Phase III Clinical Trial (FAST 1) of Icatibant for the Treatment of Hereditary Angioedema

BERLIN, April 24, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) reported today the randomization of the last patient in its Phase III clinical trial (FAST 1) of Icatibant for the treatment of hereditary...
March 28, 2006 04:20 ET | Source: Jerini AG

Jerini AG Reports Financial Results for Fiscal Year 2005

Highlights of 2005: -- EUR 96.7 million in cash and cash equivalents as of December 31, 2005 -- Successful stock market listing on Prime Standard of the Frankfurt Stock Exchange raised...
March 06, 2006 02:20 ET | Source: Jerini AG

Jerini AG Presents Clinical Development Update for Icatibant in the Treatment of Hereditary Angioedema

-- On track to report top-line Phase III results in mid-2006 -- Over 350 patients screened in 63 active sites worldwide -- 153 open-label attacks treated in Phase III trials BERLIN, March 6,...
December 01, 2005 02:16 ET | Source: Jerini AG

Jerini Reports Increase in Revenues for Third Quarter and for the First Nine Months

BERLIN, Dec. 1, 2005 (PRIMEZONE) -- Jerini CEO Schneider-Mergener: "Our partnership with U.S.-based Kos provides the basis for realizing the excellent market potential of Icatibant in North...
November 07, 2005 03:03 ET | Source: Jerini AG

Kos and Jerini Sign Exclusive Collaboration and License Agreement for Development, Marketing and Distribution of Icatibant in The United States and Canada

-- Kos to develop, market and distribute Icatibant in the U.S. and Canada -- Icatibant, in final Phase III clinical trials for hereditary angioedema (HAE), represents next potential new...